Hematologic Oncology Update

Featuring an interview with Dr Douglas W Sborov, including the following topics:
DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)
Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)
Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)
Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48)
Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00)
Prevention and management of ophthalmic events related to treatment with belamaf (21:27)
Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49)
Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27)
Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53)

CME information and select publications

Featuring an interview with Prof Andreas Hochhaus, including the following topics:
Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)
Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)
Potential mechanisms of adverse events documented with TKIs (10:23)
Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23)
Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14)
Comparative efficacy of asciminib and other agents used to treat CML (40:01)
Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53)
Practical care strategies for CML patients; future developments (52:32)

CME information and select publications

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:
Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)
Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48)
Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29)

CME information and select publications

Featuring perspectives from Prof John Seymour, including the following topics:
Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)
Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)
First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)

CME information and select publications

Featuring perspectives from Dr William G Wierda, including the following topics:
Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00)
Sequencing Road Map (12:39)
Key Datasets — Pirtobrutinib (21:08)
Investigator Survey (34:09)
Chimeric Antigen Receptor T-Cell Therapy (45:08)
Other Novel Therapy Approaches (49:58)
EHA 2026 (54:45)

CME information and select publications